Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers

Ošťádal, Petr; Vondráková, Dagmar; Krüger, Andreas; Janotka, Marek; Psotova, Hana; Průcha, M

doi:10.1186/1476-511x-11-153

Cited by 13 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, most of studies were based on single measurement of circulating Lp-PLA2, [ 7 – 12 , 21 ] and only a few observed the change of Lp-PLA2 over time. [ 16 , 17 ] Ostadal et al [ 16 ] found that serum levels of Lp-PLA2 were significantly elevated in patients with ACS, but decreased within the first 24 hours after admission and subsequently remained stable. In our study, dynamic changes in Lp-PLA2 were observed.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, some studies demonstrated that the Lp-PLA2 concentration was high at first and decreased gradually in patients with ACS over the first 3 days following hospital admission and then remained stable. [ 16 , 17 ] By contrast, Kocak et al found that Lp-PLA2 enzyme activity was significantly lower during the early stage of ACS. [ 18 ]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome

Wang²,

Tian³

et al. 2018

Medicine

View full text Add to dashboard Cite

Lipoprotein-associated phospholipase A2 (Lp-PLA2) probably plays an important role in the development of acute coronary syndrome (ACS). However, alterations of Lp-PLA2 levels during ACS and its association with cardiovascular outcome are unclear. Our aim was to investigate the change in Lp-PLA2 and its association with cardiovascular outcome in patients with ACS.A total of 79 patients with ACS came from the coronary care unit (CCU) between June 1, 2015 and August 31, 2016 in this longitudinal study. Serum levels of Lp-PLA2, troponin I, and creatine kinase isoenzymes MB (CK-MB) were measured at admission, on the first morning (D1), on the second morning of hospitalization (D2), and on the last second morning before discharge (D4). The patients were followed up till November 30, 2016. The primary outcomes were cardiovascular death and cardiovascular rehospitalization. Kaplan–Meier analysis and Cox proportional hazard models were used to identify risk factors for poor outcome in patients with ACS.All patients were followed up for 10.6 ± 4.7 months. The patients were divided into 2 groups according to the median of Lp-PLA2: lower Lp-PLA2 group and higher Lp-PLA2 group. Elevated levels of Lp-PLA2 significantly decreased during the early phases of ACS in higher Lp-PLA2 group. And Lp-PLA2 level increased at first and then decreased in lower Lp-PLA2 group. Kaplan–Meier analysis showed that patients with elevated Lp-PLA2 had a lower cardiovascular event-free survival (log-rank χ2 = 4.736, P = .030) than those with lower Lp-PLA2. Cox regression analysis indicated that high Lp-PLA2 level (hazard ratio [HR] = 1.005, 95% confidence interval [CI] = 1.002–1.008, P = .003), time delay from symptom onset to admission (HR = 1.088, 95% CI = 1.038–1.139, P < .001) independently predicted cardiovascular event in patients with ACS after adjusting for potential confounders.Serum level of Lp-PLA2 altered considerably during the early phase of ACS and increased Lp-PLA2 independently predicted cardiovascular outcome in patients with ACS after adjustment for potential confounders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome

Wang²,

Tian³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…The data regarding the correlation of Lp-PLA2 changes and hsCRP changes with statin or non-statin therapy obtained in the present study are in line with those in other reports. Ostadal et al reported that no association was observed between the alterations in the levels of Lp-PLA2 and C-reactive protein (CRP; r=0.06, P=0.70) ( 26 ). Another study also reported a lack of correlation between Lp-PLA2 and CRP ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction

et al. 2017

View full text Add to dashboard Cite

Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the progression of atherosclerosis. The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI). A total of 135 patients were enrolled in the study within 24 h of AMI, and were randomized to receive 10 mg rosuvastatin or 10 mg rosuvastatin plus 10 mg ezetimibe daily. HsCRP, Lp-PLA2, total cholesterol (TC), triglycerides (TG), LDL-C and high-density lipoprotein cholesterol (HDL-C) were determined at baseline and after 1, 3, 6 and 12 months of treatment. The addition of ezetimibe to rosuvastatin led to greater reduction of LDL-C compared with rosuvastatin monotherapy (from 3.00 to 1.19 mmol/l vs. 2.93 to 1.49 mmol/l, respectively; P<0.05), as well as reduced levels of hsCRP (from 5.15 to 0.68 mg/l vs. 4.33 to 1.49 mg/l, respectively; P<0.05) and Lp-PLA2 (from 333.13 to 79.07 mg/l vs. 327.95 to 123.62 mg/l, respectively; P<0.05). A positive association was identified between reductions of Lp-PLA2 and the changes of LDL-C (r=0.367; P=0.002). However, no significant correlation was observed between changes in Lp-PLA2 and hsCRP (r=0.264; P=0.512). The values of hsCRP and Lp-PLA2 appeared to increase during the first week after randomization, but dropped steeply to a lower level and remained stable thereafter. In conclusion, the addition of ezetimibe to rosuvastatin was demonstrated to further reduce LDL-C, hsCRP and Lp-PLA2 compared with rosuvastatin monotherapy in patients with AMI.

show abstract

“…102 In a recent cohort study, the associations among coronary plaque volume, lipid profiles and circulating Lp-PLA2 levels were analyzed in 40 patients with ACS who had undergone successful percutaneous coronary intervention. Dynamic alterations in Lp-PLA2 have been seen in early stages of acute coronary syndrome (ACS), indirectly supporting the hypothesis of an active role for Lp-PLA2 in the pathogenesis of CHD.…”

Section: Lipoprotein-associated Phospholipase A2mentioning

confidence: 99%

New and Emerging Risk Factors for Coronary Heart Disease

Akhabue

Thiboutot

Cheng

et al. 2014

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers

Cited by 13 publications

References 12 publications

Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome

Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction

New and Emerging Risk Factors for Coronary Heart Disease

Contact Info

Product

Resources

About